teprotumumab
Phase 3- Indications
- Graves' Orbitopathy
Company intelligence / Profile preview
River Vision Development Corp.
New York, New York, United Statesorpha.net ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Teprotumumab showed positive results in a Phase 2 trial for TED, published in The New England Journal of Medicine. This supported initiation of a pivotal Phase 3 study after acquisition[1][3].
- Therapeutic areas
- OphthalmologyEndocrinology
- Modalities
- Fully human monoclonal antibody (mAb)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on River Vision Development Corp..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on River Vision Development Corp..